

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Sebetralstat for treating acute attacks of hereditary angioedema in people 12 years and over [ID6284]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
	<ol style="list-style-type: none">1. A stakeholder considered that the technology should be available to all HAE patients with all types of HAE.2. The 3 available C1-esterase inhibitors (listed as comparators in the scope) are derived from either human plasma (Cinryze and Berinert) or animal (rabbit) DNA (Ruconest). Some people of certain religions, such as Jehovah's Witness, are unable to accept donor blood products.
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
	<ol style="list-style-type: none">1. Sebetralstat will be appraised within its marketing authorisation or a population for whom the company provides evidence if this is narrower than the marketing authorisation. If the marketing authorisation includes all types of HAE, the committee, where relevant, may consider whether the evidence is generalisable to all types of HAE.2. Consideration should be given to the treatment options available for individuals unwilling to receive human or animal products, ensuring that any recommendations neither directly nor indirectly discriminate based on religion.

--

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
----	---

No

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
----	---

No

Approved by Associate Director (name): Ross Dent

Date: 05/03/2025